Galectin-3: Differential expression between small-cell and non-small-cell lung cancer

Histopathology

Volumn 44, Issue 4, 2004, Pages 339-344

  Buttery, R ^a   Monaghan, H ^b   Salter, D M ^b   Sethi, T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy; Galectin 3; Histology; Lung cancer

Indexed keywords

BIOTIN; GALAPTIN; GALECTIN 3; STREPTAVIDIN;

ARTICLE; CARCINOGENESIS; CAUSE OF DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 1842866297     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01815.x     Document Type: Article

References (34)

1. Fushimi H, Kikui M, Morino H et al. Histologic changes in small cell lung carcinoma after treatment. Cancer 1996: 77; 278-283.
2. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 1994: 269; 20807-20810.
3. Hughes RC. Mac-2: a versatile galactose-binding protein of mammalian tissues. Glycobiology 1994: 4; 5-12.
4. Barondes SH, Castronovo V, Cooper DN et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994: 76; 597-598.
5. Gong HC, Honjo Y, Nangia-Makker P et al. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 1999: 59; 6239-6245.
6. Birdsall B, Feeney J, Burdett ID, Bawumia S, Barboni EA, Hughes RC. NMR solution studies of hamster galectin-3 and electron microscopic visualization of surface-adsorbed complexes: evidence for interactions between the N-and C-terminal domains. Biochemistry 2001: 40; 4859-4866.
7. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self association of galectin-3. Biochemistry 1998: 37; 4086-4092.
8. Cvejic D, Savin S, Golubovic S, Paunovic I, Tatic S, Havelka M. Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology 2000: 37; 530-535.
9. Baldus SE, Zirbes TK, Weingarten M et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000: 21; 258-266.
10. Schaffert C, Pour PM, Chaney WG. Localization of galectin-3 in normal and diseased pancreatic tissue. Int. J. Pancreatol. 1998: 23; 1-9.
11. Honjo Y, Inohara H, Akahani S et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin. Cancer Res. 2000: 6; 4635-4640.
12. van den Brule FA, Buicu C, Berchuck A et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum. Pathol. 1996: 27; 1185-1191.
13. Castronovo V, van den Brule FA, Jackers P et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol. 1996: 179; 43-48.
14. Lotz MM, Andrews CW Jr, Korzelius CA et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc. Natl Acad. Sci. USA 1993: 90; 3466-3470.
15. Bresalier RS, Mazurek N, Sternberg LR et al. Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 1998: 115; 287-296.
16. Yoshimura A, Gemma A, Hosoya Y et al. Increased expression of the LGALS3 (galectin 3) gene in human non-small-cell lung cancer. Genes Chromosomes Cancer 2003: 37; 159-164.
17. Berberat PO, Friess H, Wang L et al. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J. Histochem. Cytochem. 2001: 49; 539-549.
18. Irimura T, Matsushita Y, Sutton RC et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res. 1991: 51; 387-293.
19. Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res. 1998: 18; 2637-2641.
20. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J. Biol. Chem. 2002: 277; 6852-6857.
21. O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I, Clynes M. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res. 2002: 22; 3117-3125.
22. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000: 21; 1941-1945.
23. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am. J. Pathol. 2001: 159; 1055-1060.
24. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999: 59; 4148-4154.
25. Matarrese P, Fusco O, Tinari N et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J. Cancer 2000: 85; 545-554.
26. Matarresea P, Tinari N, Semeraroa ML, Natolib C, Iacobelli S, Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Letters 2000: 473; 311-315.
27. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl Acad. Sci. USA 1996: 93; 6737-6742.
28. Dagher SF, Wang JL, Patterson RJ. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc. Natl Acad. Sci. USA 1995: 92; 1213-1217.
29. Openo KP, Kadrofske MM, Patterson RJ, Wang JL. Galectin-3 expression and subcellular localization in senescent human fibroblasts. Exp. Cell Res. 2000: 255; 278-290.
30. Cherayil BJ, Weiner SJ, Pillai S. The Mac-2 antigen is a galactose-specific lectin that binds IgE. J. Exp. Med. 1989: 170; 1959-1972.
31. Sato S, Hughes RC. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J. Biol. Chem. 1994: 269; 4424-4430.
32. Rintoul RC, Buttery RC, MacKinnon AC et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol. Biol. Cell 2002: 13; 2841-2852.
33. Warren AP, Patel K, McConkey DJ, Palacios R. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoletic cells. Blood 1996: 87; 3676-3687.
34. Diaz LA Jr, Fox DA. A role for CD98 in cellular activation. J. Biol. Regulators Homeostatic Agents 1998: 12; 25-32 [Review].